Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atiere Intensive is a hyaluronic acid-based dermal filler developed by Medytox, a South Korean biopharmaceutical company. It is specifically indicated for the correction of deep facial wrinkles and the restoration of facial volume. The product is manufactured using Medytox's proprietary H.E.A.R.T. (High, Elastic, Advanced, Rheological, Throughput) technology, which ensures optimal viscoelastic properties for deep tissue integration. The formulation consists of cross-linked, non-animal derived hyaluronic acid at a concentration of 20-24 mg/mL, combined with 0.3% lidocaine to enhance patient comfort during the injection procedure. As a medical device, it provides immediate physical filling and structural support, with aesthetic results typically maintained for 12 to 18 months.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atiere Intensive.